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Abstract Differential glycosylation of human and rat (r)
calcitonin (CT) receptor-like receptors (CRLR) as a result of
interactions with accessory receptor activity-modifying proteins
(RAMP)1 or -2 was considered to define CT gene-related peptide
(CGRP) or adrenomedullin (ADM) receptors in mammalian
cells. Here, Drosophila Schneider (S2) cells stably co-expressed
rCRLR and RAMP1 or -2 as functional CGRP or ADM
receptors. Different from mammalian cells, rCRLR expressed in
S2 cells are uniformly glycosylated proteins independent of
RAMP1 or RAMP2. Bis(sulfosuccinimidyl)suberate cross-link-
ing revealed receptor components with the size of rCRLR,
increased by the molecular weights of the corresponding RAMPs
and [125I]CGRP or [125I]ADM. In conclusion, [125I]CGRP/
rCRLR/RAMP1 and [125I]ADM/rCRLR/RAMP2 complexes
have been recognized in Drosophila S2 cells.
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1. Introduction
Calcitonin (CT) gene-related peptide (CGRP), adrenome-
dullin (ADM), CT and amylin are homologous peptides
with 6- or 7-amino acid ring structures and amidated car-
boxy-termini required for biological activity [1]. CGRP and
ADM are potent vasorelaxant and hypotensive peptides with
positive inotropic action on the heart. Along these lines,
CGRP was shown to have therapeutic potential in cardiovas-
cular disorders [1]. An enhanced survival rate of ADM-over-
expressing transgenic mice in response to lipopolysaccharide
administration suggested a protective action of the peptide in
septic shock preventing severe hypotension [2]. Therapeutic
use of CGRP and ADM awaits the development of corre-
sponding low molecular weight non-peptide mimics with suit-
able bioavailability. This requires so far non-existing high
throughput in vitro screening systems, using cell lines that
express a high density of CGRP and ADM receptors.
Initially orphan human (h) and rat (r) CT receptor-like
receptors (CRLR) of the B family of G protein-coupled re-
ceptors are CGRP or ADM receptors when co-expressed with
human receptor activity modifying protein RAMP1 or
RAMP2, respectively [3,4]. RAMP1 and RAMP2 have been
shown to direct CRLR to the cell surface. Mature glycosyla-
tion of CRLR occurred in the presence of RAMP1 and core-
glycosylation was observed when CRLR was expressed alone
or together with RAMP2. Di¡erential glycosylation was con-
sidered as a mechanism to de¢ne the speci¢city of CGRP and
ADM receptors.
Drosophila cell lines, in particular the baculovirus/Sf9 cell
system, are powerful and versatile expression systems for het-
erologous proteins that require posttranslational modi¢cation
for proper function. But Sf9 cells die from baculovirus infec-
tion which is not the case with Drosophila Schneider 2 (S2)
cells [5]. The latter are suitable for the continuous production
in suspension culture at high cell density and room temper-
ature of a variety of stably transfected heterologous proteins
such as the glucagon receptor [6].
Here, Drosophila S2 cell lines have been developed that
stably express CGRP or ADM receptors as rCRLR/RAMP1
or rCRLR/RAMP2 complexes, recognized for the ¢rst time,
at the cell surface.
2. Materials and methods
2.1. Materials
Rat and human KCGRP(1^37) and rat amylin were purchased from
Bachem AG (Bubendorf, Switzerland); rLCGRP(1^37), rKCGRP(8^
37) and rCT from Peninsula Laboratories (Belmont, CA, USA);
rADM(1^50) from Peptide Institute (Osaka, Japan); and rADM(20^
50) from Phoenix Pharmaceuticals (Mountain View, CA, USA). Cul-
ture media and FCS were obtained from Biological Industries (Kib-
butz Beit Haemek, Israel). Hygromycin B was from Life Technologies
(Gaithersburg, MD, USA). N-glycosidase F was supplied by Boehr-
inger Mannheim (Mannheim, Germany). 125I-Na and ECL Western
blot detection reagents were obtained from Amersham International
(Little Chalfont, UK), and anti-V5 horseradish peroxidase (HRP)-
labeled antibody was from Invitrogen (Carlsbad, CA, USA). The
membrane impermeable, water-soluble crosslinker bis(sulfosuccinimi-
dyl)suberate (BS3) was supplied by Pierce (Rockford, IL, USA).
Chemicals and other reagents were purchased from Sigma (St. Louis,
MO, USA) and E. Merck (Darmstadt, Germany) at the highest grade
available.
2.2. Expression of rCRLR and RAMP1 and RAMP2 in Drosophila
S2 cells
The vector pAc5.1/V5-His (Invitrogen, Carlsbad, CA, USA) was
used for constitutive expression of rCRLR and RAMP1 and
RAMP2 fused to carboxy-terminal V5- and His6-epitopes in Droso-
phila S2 cells. Brie£y, coding sequences of RAMP1 and RAMP2 with
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the translational stop sites removed, were ampli¢ed by PCR from
cloned cDNA (provided by S. Foord, Glaxo Wellcome, Stevenage,
UK). Oligonucleotide primers were designed with 5P KpnI and 3P
XbaI (RAMP1) and with 5P EcoRI and 3P NotI (RAMP2) restriction
sites for unidirectional cloning into pAc5.1/V5-His in frame with vec-
tor-encoded V5-His6-epitopes. Similarly, a DNA fragment spanning
the coding sequence of rCRLR between a unique internal HindIII
restriction site and the translation stop codon was ampli¢ed from
cloned rCRLR encoding cDNA (provided by M.G. Rosenfeld, Uni-
versity of California, San Diego, CA, USA). Cloning of this PCR
product carrying 5P HindIII and 3P XhoI restriction sites, and of a
NotI/HindIII restriction fragment encoding the remaining amino-ter-
minal portion of rCRLR into NotI/XhoI digested pAc5.1/V5-His
yielded the expression construct for a rCRLR-V5-His6 fusion protein.
All constructs were veri¢ed by sequencing before the transformation
of insect cells.
The cells were maintained in suspension culture at 23‡C in Schnei-
der’s Drosophila medium supplemented with 10% heat-inactivated fe-
tal calf serum. 107 S2 cells were co-transfected by CaPO4 precipitation
(Invitrogen, Carlsbad, CA, USA) with 19 Wg of the vector pAc5.1/V5-
His (mock transfections) or rCRLR, hRAMP1 or -2 expression con-
structs in pAc5.1/V5-His or combinations thereof, and with 1 Wg of
the hygromycin resistance plasmid pCoHYGRO (Invitrogen, Carls-
bad, CA, USA). 24 h after transfection 300 Wg/ml hygromycin-B was
added to the medium. The medium was changed every 4 days. Stably
transfected, polyclonal hygromycin-resistant cell lines were obtained
after 3^4 weeks and subcultured (1:5 dilution) every 3^4 days.
2.3. Radioligand binding and cAMP accumulation
125I-labeled hKCGRP and [125I]rADM were prepared as previously
described [4]. Aliquots of 0.5U106 S2 cells were incubated for 1 h at
4‡C with 1700 Bq [125I]hKCGRP or [125I]rADM in the absence and
presence of non-labeled peptides in a total volume of 200 Wl DMEM/
Ham F12 (1:1) supplemented with 0.1% BSA (binding medium). Sub-
sequently, the cells were collected by centrifugation at 14 000Ug and
4‡C for 5 min, and the supernatant was aspirated. The tip of the tube
containing the cell pellet was cut o¡ and bound radioligand was
estimated in a Q-counter (MR252, Kontron, Zurich, Switzerland). Ra-
dioactivity in the pellet of cells that were incubated in the presence of
0.1 WM non-labeled peptides was considered as non-speci¢c binding.
Cyclic AMP accumulation was measured in 2U106 S2 cells incubated
at room temperature for 15 min in 200 Wl Schneider’s Drosophila
medium containing 1 mM isobutylmethylxanthine (IBMX) in the ab-
sence and presence of the indicated peptides. The cells were collected
by centrifugation at 1000Ug and room temperature for 5 min and
cAMP was measured as described [4].
2.4. Cross-linking of cell surface proteins, deglycosylation and
Western blot analysis
For the cross-linking analysis 2.5U106 S2 cells, stably expressing
CGRP or ADM receptors, were incubated for 1 h at 4‡C with 6700
Bq [125I]hKCGRP or [125I]rADM in the absence and presence of non-
labeled CGRP and ADM in 400 Wl binding medium. Subsequently,
the cells were collected by centrifugation at 14 000Ug and 4‡C for
5 min. The cells were resuspended in 400 Wl 0.1 M PBS and incubated
for 40 min with 1 mM membrane-impermeable cross-linker BS3. The
reaction was quenched with 1 M Tris^HCl, pH 7.5. The cells were
collected by centrifugation at 14 000Ug at room temperature for 5 min
and resuspended in 50 mM Tris^HCl, pH 7.8, 150 mM NaCl, 1%
Nonidet P-40. The cell lysates were cleared by centrifugation at
14 000Ug at room temperature for 5 min and the supernatants were
kept at 320‡C for further analysis. Deglycosylation of proteins in
lysates of S2 cells was carried out with N-glycosidase F. Aliquots,
equivalent to 2^2.5U106 cells, were incubated for 18 h at 37‡C in
50 Wl 10 mM Tris^HCl, pH 7.5, 10 mM EDTA, 0.1% SDS, 0.5%
octylglucopyranoside, 1% L-mercaptoethanol in the absence and pres-
ence of 4 U N-glycosidase F. The incubations were stopped with
protein gel loading bu¡er (0.25 M Tris^HCl, pH 6.8, 0.4% bromo-
phenol blue, 8% L-mercaptoethanol, 8% SDS, 40% glycerol). The
proteins were separated by 15% Tris^glycine SDS polyacrylamide
gel electrophoresis and transferred to nitrocellulose Hybond1
ECL1 (Amersham International, Little Chalfont, UK) in 14.4 g/l
glycine, 3.03 g/l Tris, 20% methanol in a Trans-Blot cell (Bio-Rad
Laboratories, Richmond, CA, USA) at 25 V and 4‡C overnight.
V5- and His6-tagged rCRLR and RAMPs were visualized with per-
oxidase-labeled anti-V5 (1:5000 ¢nal dilution) monoclonal antibodies
according to the protocol of the ECL Kit (Amersham International,
Little Chalfont, UK). Biotinylated protein size markers were visual-
ized by ECL according to the manufacturer’s instructions. Cross-
linked [125I]hKCGRP and [125I]rADM were detected with Hyper¢lm1
MP ¢lm (Amersham International, Little Chalfont, UK).
2.5. Statistics
The values for half-maximal inhibitory concentrations (IC50) and
for half-maximal e¡ective concentrations (EC50) were calculated by
non-linear regression analysis using Fig. P 6.0 software (Biosoft, Cam-
bridge, UK).
3. Results and discussion
3.1. CGRP and ADM receptor function in Drosophila S2 cells
Rat CRLR and RAMP1 and RAMP2 with carboxy-termi-
nal V5- and His6-epitope tags were stably expressed in S2 cells.
In control transfected cells and in cells transfected with indi-
vidual RAMP1, RAMP2 and rCRLR encoding cDNA alone,
speci¢c binding of [125 I]hKCGRP and [125 I]rADM was not
Fig. 1. Binding of [125I]hKCGRP (top) and [125I]rADM (bottom) to
Drosophila S2 cells stably expressing combinations of rCRLR and
RAMPs. Open bars indicate total binding and closed bars non-spe-
ci¢c binding in the presence of 1036 M non-labeled corresponding
peptides. The empty Drosophila expression vector pAc5.1/V5-His
was used for mock transfections and to equalize the total amounts
of DNA in individual transfections. Binding conditions are de-
scribed in Section 2. The results are mean values þ S.E.M. of tripli-
cate determinations of experiments carried out at least three times.
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detected (Fig. 1). Speci¢c [125I]hKCGRP binding was 17% of
added radioligand in the cells co-expressing rCRLR and
RAMP1, but not with RAMP2. Rat CRLR and RAMP2
co-expressing cells, on the other hand, exhibited 16% speci¢c
[125I]rADM, but no [125I]hKCGRP binding. In cells co-ex-
pressing rCRLR and RAMP1 [125I]hKCGRP binding was dis-
placed by rKCGRP(1^37), rLCGRP(1^37) and the CGRP an-
tagonist rKCGRP(8^37) with similar half-maximal inhibitory
concentrations (IC50), and rADM(1^50) was 18-fold less po-
tent than rKCGRP(1^37) (Table 1). The ADM antagonist
rADM(20^50), rat amylin and rCT did not a¡ect
[125I]hKCGRP binding at up to 0.5 WM. In the S2 cells co-
expressing rCRLR and RAMP2 [125I]rADM binding was
most potently inhibited by rADM(1^50), and rADM(20^50),
rKCGRP(1^37), rLCGRP(1^37) and rKCGRP(8^37) were 16-
and 260-fold less e¡ective than rADM(1^50). [125I]rADM
binding was una¡ected by up to 1 WM rat amylin and rCT.
The IC50 of rKCGRP(1^37), rLCGRP(1^37) and of rADM(1^
50) of [125I]hKCGRP and -rADM receptor binding corre-
sponded to the half-maximal e¡ective concentration (EC50)
of cAMP accumulation. Taken together, CGRP and ADM
receptors expressed in S2 cells co-transfected with rCRLR
and RAMP1 or RAMP2 encoding cDNA exhibited the phar-
macological pro¢le and coupling to cAMP production indis-
tinguishable from that of the receptors expressed in mamma-
lian cells [3,4]. The results also indicate that Drosophila S2 cells
do not express recognizable amounts of endogenous homo-
logues of rCRLR, RAMP1 and RAMP2 interfering with the
functional expression of mammalian CGRP or ADM recep-
tors.
3.2. Glycosylation of rCRLR and RAMPs in Drosophila
S2 cells
Glycosylation of V5- and His6-epitope tagged rCRLR and
RAMP1 and RAMP2, stably expressed in S2 cells, was ana-
lyzed on Western blots in the absence and presence of
N-glycosidase F (Fig. 2). Rat CRLR alone or together with
RAMP1 or RAMP2 had an indistinguishable apparent Mr of
55^59 kDa reduced to 48 kDa through treatment with
N-glycosidase F. The latter corresponds to the protein back-
bone of rCRLR. In S2 cells glycosylated rCRLR is similar in
size to the hCRLR [3] and rCRLR (not shown) in human
embryonic kidney (HEK) cells alone and with RAMP2. In
HEK cells RAMP1 brought about more extensive glycosyla-
tion of hCRLR [3] and rCRLR (not shown) to 66 and 74 kDa
components, respectively, not recognized in Drosophila S2
cells. RAMP1 expressed in Drosophila S2 cells had an appar-
ent Mr of 15 kDa, as predicted from the amino acid sequence,
unaltered by N-glycosidase F. RAMP2, on the other hand,
had a predominant 18 kDa Mr reduced by N-glycosidase F
to a major 16 kDa protein in agreement with the calculated
Mr of non-glycosylated RAMP2. This demonstrates glycosyl-
ation of RAMP2, but not of RAMP1. The ¢ndings are con-
sistent with a single N-glycosylation site predicted from the
amino acid sequence of RAMP2 not conserved in RAMP1 [3].
Taken together, the results demonstrate glycosylation of
rCRLR and RAMP2 in Drosophila S2 cells. Moreover, glyco-
sylation of the rCRLR in S2 cells is independent of the pres-
ence of RAMP1 or RAMP2 and does not indicate CGRP or
ADM speci¢city.
3.3. Characterization of [125I]hKCGRP and
[125I]rADM-binding protein components in S2 cells
The [125I]hKCGRP was cross-linked with BS3 to Drosophila
S2 cells co-expressing V5- and His6-epitope tagged rCRLR
Table 1
[125I]hKCGRP and [125I]rADM binding inhibition (IC50) and cAMP accumulation (EC50) in Drosophila S2 cells transfected with rCRLR togeth-
er with RAMP1 and RAMP2
rCRLR+RAMP1 rCRLR+RAMP2
IC50 (nM) EC50 (nM) IC50 (nM) EC50 (nM)
rKCGRP(1^37) 6.5 þ 2.2 10.7 þ 3.2 225 þ 35 s 1000
rLCGRP(1^37) 4.7 þ 0.72 5.1 þ 0.3 190 þ 46 s 1000
rKCGRP(8^37) 1.7 þ 0.36 s 1000 97 þ 19 s 1000
rADM(1^50) 118 þ 19 s 1000 0.87 þ 0.2 7.7 þ 3.6
rADM(20^50) s 1000 s 1000 14 þ 8.6 s 1000
Rat amylin s 500 s 1000 s 1000 s 1000
rCT s 1000 s 1000 s 1000 s 1000
Results are means þ S.E.M. of three independent experiments
Fig. 2. Glycosylation of rCRLR and RAMP1 and RAMP2 revealed
by Western blot analysis. Extracts of S2 cells, stably expressing V5-
and His6-epitope tagged rCRLR and RAMP1 or RAMP2 in indi-
cated combinations, were subjected to SDS polyacrylamide (15%)
gel electrophoresis with and without N-glycosidase F treatment. The
proteins were visualized on Western blots with monoclonal V5-anti-
body and the ECL technique (see Section 2). Representative experi-
ment carried out at least three times.
FEBS 23524 7-4-00
A. Aldecoa et al./FEBS Letters 471 (2000) 156^160158
and RAMP1. Polyacrylamide gel electrophoresis of cell ex-
tracts and autoradiography of Western blots revealed major
speci¢cally 125I-labeled proteins between 63 and 71 kDa and a
minor 18 kDa component (Fig. 3, top). The radiolabeled pro-
teins were not observed when the cross-linker was omitted.
Treatment of cross-linked samples with N-glycosidase F re-
duced the size of the large 63^71 to 51^68 kDa proteins, but
the 18 kDa radiolabeled component remained unchanged.
Similarly, cross-linking of [125I]rADM to S2 cells co-express-
ing V5- and His6-epitope tagged rCRLR and RAMP2 re-
vealed two speci¢cally labeled components with apparent
Mr of 72^76 and 64^67 kDa. The latter were reduced with
N-glycosidase F to 54^58 kDa.
Subsequent analysis of the same Western blot with V5-epi-
tope speci¢c antibodies was carried out to further characterize
[125I]hKCGRP- and [125I]rADM-binding proteins. In extracts
of rCRLR and RAMP1 or RAMP2 co-expressing S2 cells not
treated with cross-linker, glycosylated rCRLR and RAMP2,
and RAMP1 were observed (Fig. 3, bottom). In cell extracts
treated with BS3 additional major protein components were
detected in the position of [125I]hKCGRP- and [125I]rADM-
binding components, identi¢ed by autoradiography. They
were only recognized when RAMP1 or RAMP2 were co-ex-
pressed with rCRLR and the Mr were consistent with those of
glycosylated rCRLR cross-linked to RAMP1 or to glycosylat-
ed RAMP2. Moreover, decreased amounts of free RAMP1
and RAMP2 were observed in cross-linked as compared to
non-cross-linked samples, consistent with a shift of a fraction
of the two RAMPs into larger molecular weight cross-linking
products like rCRLR/RAMP complexes. Additional minor
non-identi¢ed components, recognized by the V5-antibody,
with apparent Mr of 20^46 kDa were also observed. These
minor cross-linking products in extracts of rCRLR/RAMP1
co-expressing cells had not a Mr of 18 kDa expected for
[125I]hKCGRP cross-linked to RAMP1. But the weak auto-
radiographic signal at 18 kDa indicated that the amounts of
this cross-linking product were likely below the detection limit
of the V5-antibodies and represented a minor fraction of
[125I]hKCGRP cross-linked to RAMP1 alone slightly larger
than RAMP1. Interaction on the cell surface of
[125I]hKCGRP with RAMP1 alone cannot be excluded. Evi-
dence for RAMP2 cross-linked to [125I]rADM has not been
obtained.
Deglycosylated proteins were recognized in S2 cells follow-
ing treatment with N-glycosidase F. In S2 cells co-expressing
rCRLR and RAMP1 or RAMP2 and treated with cross-
linked major protein components di¡ered in size from the
48 kDa rCRLR by the Mr predicted for RAMP1 and non-
glycosylated RAMP2, respectively. In the same samples recep-
tor autoradiography indicated cross-linking of [125I]hKCGRP
to a deglycosylated rCRLR/RAMP1 complex and to rCRLR
alone. In rCRLR and RAMP2 co-expressing cells correspond-
ing [125I]rADM/rCRLR/RAMP2 and [125I]rADM/rCRLR
complexes were also observed. But the larger [125I]rADM-la-
beled component was unaltered following N-glycosidase F
treatment, indicating that a rCRLR/RAMP2 complex was
resistant to N-glycosidase-F when bound to [125I]rADM.
In a parallel study carried out in mammalian cells (in prep-
aration), myc-tagged RAMP1 was similarly cross-linked to
[125I]hKCGRP-binding V5- and His6-tagged rCRLR. The re-
sults presented here and the observations obtained in mam-
malian cells demonstrate that the predicted co-transport of
CRLR and RAMPs to the plasma membrane [3] results in
the formation of CRLR/RAMP1 or CRLR/RAMP2 hetero-
dimers on the cell surface that function as speci¢c CGRP or
ADM receptors in Drosophila and mammalian cells. This and
the identi¢cation of amino-terminal putative extracellular do-
mains of RAMP1/RAMP2 chimeras as the critical determi-
nants of ligand speci¢city [7], imply direct interactions of ex-
tracellular domains of RAMP1 and RAMP2 with CRLR
de¢ning the ligand binding site. The here established polyclon-
al Drosophila S2 cell lines, stably co-expressing V5- and His6-
epitope tagged rCRLR and RAMP1 or RAMP2, are suitable
for large scale suspension culture.
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Fig. 3. BS3-cross-linking of [125I]hKCGRP to Drosophila S2 cells
that express rCRLR and together with RAMP1 (lanes a^h) or of
[125I]rADM to cells that co-express rCRLR and RAMP2 (lanes i^
q). Cross-linker and non-labeled peptides were added and the cell
extracts treated with N-glycosidase F as indicated. After SDS poly-
acrylamide gel electrophoresis of cell extracts, Western blots were
autoradiographed (top) and analyzed with V5-antibody (bottom).
Representative experiment carried out at least three times.
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